Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
Products Gliptins are commercially available in the form of film-coated tablets. Sitagliptin (Januvia) was the first representative to be approved in the United States in 2006. Today, various active ingredients and combination products are commercially available (see below). They are also called dipeptidyl peptidase-4 inhibitors. Structure and properties Some gliptins have a proline-like structure because … Gliptine
